__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

The Psoriasis Epidemiology Screening Tool (PEST) is a short validated questionnaire that is effective and easy to use in clinical practice. It comprises five questions that HCPs should ask psoriasis patients every year.1

Why is PEST important?

BAD and NICE recommend that patients with psoriasis who have not been diagnosed with psoriatic arthritis (PsA) should be actively screened with an annual PEST questionnaire.2,3 

nearly 85% of patients with PsA developpsoriasis first

up to 40% of patients with psoriasis have PsA

 

PEST scores can be used to identify PsA in psoriasis patients, early on. This can have an effect on their overall outcomes, since the PEST result may affect the choice of biologic selected to manage the patient.2,3

BAD recommends consideration of rheumatology referral for patients with a score of ≥3. Research suggests that an even lower PEST score, of ≥2, may indicate PsA.1

Take a look at how the experts are using PEST in their practices. 

 

You can start using PEST in your practice now

Download PEST

Reproduced PEST with permissions from Professor Helliwell at the University of Leeds

BAD, British Association of Dermatologists; NICE, National institute for Health and Care Excellence.

References

  1. Mease PJ et al. J Eur Acad Dermatol Venereol. 2019;33(5):886-892.
  2. BAD. Psoriasis Epidemiology Screening Tool (PEST). Available from: https://www.bad.org.uk/shared/get-file.ashx?id=1655&itemtype=document [Accessed May 2021].
  3. NICE. Psoriasis: assessment and management. Updated 2017. Available from: https://www.nice.org.uk/guidance/cg153/resources/psoriasis-assessment-an... [Accessed May 2021].
  4. Giannelli A. Rheumatol Ther. 2019;6:5-21.
  5. Mease PJ et al. J Am Acad Dermatol. 2013;69(5):729-735
  6. Tucker LJ et al. Curr Rheumatol Rep. 2018;20(11):71.
  7. Reich K et al. Br J Dermatol. 2009;160(5):1040-1047.
  8. Richette P et al. Ann Rheum Dis. 2013;72(4):566-571.
Rate this content: 
No votes yet
UK | June 2021 | 131858
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]